Sun Pharma Advanced Research Company (SPARC) is currently trading at Rs. 150.60, down by 3.60 points or 2.33% from its previous closing of Rs. 154.20 on the BSE.
The scrip opened at Rs. 150.90 and has touched a high and low of Rs. 152.80 and Rs. 149.00 respectively. So far 33896 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 413.40 on 31-Aug-2018 and a 52 week low of Rs. 107.00 on 09-Jul-2019.
Last one week high and low of the scrip stood at Rs. 163.55 and Rs. 149.00 respectively. The current market cap of the company is Rs. 3938.57 crore.
The promoters holding in the company stood at 68.46%, while Institutions and Non-Institutions held 4.95% and 26.58% respectively.
Abraxis Biosciences LLC has filed a complaint against Sun Pharma Advanced Research Company (SPARC) in the US District Court for the district of New Jersey. It alleged that the SPARC’s filing of New Drug Application (NDA) for Taclantis injection (Paclitaxel Injection Concentrate for Suspension) is an act of infringement of the Orange Book listed patents for Abraxane.
SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
